Antispasmodic Drugs Under Restrictive Watch by KFDA

Published: 2004-12-08 06:56:00

Updated: 2004-12-08 06:56:00

The Korea Food and Drug Administration (KFDA) announced that it would restrict approval, production and sale of seven drugs containing noraminopyrine methane sulfonate calcium (NMSC), which has an antispasmodic effect used for treatment of gastrointestinal, biliary, and urinary tract spasms, amon...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK